ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

PET-directed treatment changes during neoadjuvant therapy for esophageal and EGJ cancer: results from the ALLIANCE 80803 trial

PET-directed treatment changes during neoadjuvant therapy for esophageal and EGJ cancer: results from the ALLIANCE 80803 trial
Response group pCR rate Overall survival
Number of events for survival analysis Median (months)
(95% CI)		 2-year
(95% CI)		 5-year
(95% CI)
CP responder
(CP→CP)		 14%
(9/64)		 37/64 38.7
(20.9-NE)		 56.9
(45.9-70.6)		 43.9
(33.1-58.2)
CP nonresponder
(CP→FOLFOX)		 20%
(10/50)		 29/50 26.6
(17.1-NE)		 53
(40.8-69)		 40.4
(28.7-56.9)
FOLFOX responder
(FOLFOX→FOLFOX)		 40%
(29/72)		 33/72 NE
(3.3-NE)		 76.1
(66.8-86.7)		 53
(42.5-66.1)
FOLFOX nonresponder
(FOLFOX→CP)		 18%
(7/39)		 24/39 28.7
(20.8-NE)		 61.5
(48-78.9)		 37.5
(24.8-56.5)
pCR: pathologic complete response; CP: carboplatin plus paclitaxel; FOLFOX: oxaliplatin plus leucovorin and fluorouracil; CI: confidence interval; NE: not estimable.
Data from: Goodman KA, Ou F-S, Hall NC, et al. Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. J Clin Oncol 2021; 39:2803.
Graphic 132377 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟